Comments

Iterum Therapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Iterum Therapeutics (ITRM) operate in?

Iterum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

ITRMNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.9900

0.054.76%

At close: -

$0.9949

0.004900.49%

After Hours: 7:58 PM EDT

Iterum Therapeutics (ITRM) Forecast

News Earnings Iterum Therapeutics (ITRM) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings

Iterum Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ITRM | Benzinga

Explore Iterum Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ITRM.

Open	$0.94
Close	$0.99
Volume / Avg.	736.12K / 442.69K
Day Range	$0.93 - $1.00
52 Wk Range	0.81 - 3.02
Market Cap	$39.80M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	51
Short Interest	3.28%
Days to Cover	1.89

Recent News

Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade tariffs eroded risk appetite.

Piero Cingari

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships

Iterum Therapeutics' Orlynvah receives FDA approval for treating uncomplicated UTIs in adult women, marking its first approved indication and a U.S. first for oral penems.

Vandana Singh

Why Iterum Therapeutics Stock Is Trending Today

Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin.

Erica Kollmann

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$0.94
Close	$0.99
Volume / Avg.	736.12K / 442.69K
Day Range	$0.93 - $1.00
52 Wk Range	0.81 - 3.02
Market Cap	$39.80M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	51
Short Interest	3.28%
Days to Cover	1.89

About Iterum Therapeutics Plc

Sector

Health Care

Industry

Pharmaceuticals

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Iterum Therapeutics (ITRM) stock?

You can purchase shares of Iterum Therapeutics (NASDAQ:ITRM) through any online brokerage.

View our list of the best stock brokerages

Who are Iterum Therapeutics (ITRM) competitors?

Other companies in Iterum Therapeutics’s space includes: SCYNEXIS (NASDAQ:SCYX), CalciMedica (NASDAQ:CALC), Rani Therapeutics Hldgs (NASDAQ:RANI), Lipocine (NASDAQ:LPCN) and Cadrenal Therapeutics (NASDAQ:CVKD).

What is the forecast, or price target, for Iterum Therapeutics (ITRM) stock?

Iterum Therapeutics has a consensus price target of $7.00.

What is the current price for Iterum Therapeutics (ITRM)?

The stock price for Iterum Therapeutics (NASDAQ: ITRM) is $0.9949 last updated May 28, 2025 at 7:58 PM EDT.

Does Iterum Therapeutics (ITRM) pay a dividend?

There are no upcoming dividends for Iterum Therapeutics.

When is Iterum Therapeutics (NASDAQ:ITRM) reporting earnings?

Iterum Therapeutics’s Q2 earnings are confirmed for Wednesday, August 13, 2025.

Is Iterum Therapeutics (ITRM) going to split?

There is no upcoming split for Iterum Therapeutics.

What sector and industry does Iterum Therapeutics (ITRM) operate in?

Iterum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.